Hot Longevity Mandate: Europe-Based Pharma

6 Jul

The company is a global biotech company founded in 1929 and headquartered in Europe. The Company has three R&D facilities in the US, the UK, and France. The Company has several marketed products in oncology, rare diseases, and neurosciences and has global commercial and development capabilities. The firm is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The Company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program by leveraging the capabilities of all partners involved while meeting the needs of the entrepreneur/startup. The Company is also an anchor investor in a newly launched venture fund that will have an associated accelerator which will start / fund project focused companies to work in close partnership with company R&D. This fund will add additional flexibility in the firm’s ability to work with the early stage biotech and academic communities.

The Company is focused on enhancing its pipeline with oncology, rare disease, and select neuroscience drug assets. The firm is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.

The firm has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The firm is open to opportunities/companies on a global basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: